References
- Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
- Bross P F, Kane R, Farrell A T, Abraham S, Benson K, Brower M E, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10: 3954–3964
- Hainsworth J D, Spigel D R, Barton J, Farley C, Schreeder M, Hon J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl cancer research network. Cancer 2008; 113: 765–771
- Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832–3842
- Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
- Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29(Suppl. 1)3–9
- Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9–16
- Keats J J, Fonseca R, Chesi M, Schop R, Baker A, Chng W J, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007; 12: 131–144
- Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng W J, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177–3188
- Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304–311
- Kane R C, Bross P F, Farrell A T, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508–513
- Adams J, Palombella V J, Sausville E A, Johnson J, Destree A, Lazarus D D, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
- Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417–421
- Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
- Jagannath S, Richardson P G, Barlogie B, Berenson J R, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929–934
- Suvannasankha A, Smith G G, Juliar B E, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 131–134